Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 322Thoracic 2Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 5760Lung Neoplasms 3725Small Cell Lung Carcinoma 1021Breast Neoplasms 668Neoplasms 615Colorectal Neoplasms 562Melanoma 479Ovarian Neoplasms 435Neoplasm Metastasis 432Pancreatic Neoplasms 387Stomach Neoplasms 332Carcinoma, Renal Cell 312Adenocarcinoma of Lung 309Squamous Cell Carcinoma of Head and Neck 306Head and Neck Neoplasms 295Prostatic Neoplasms 285Mesothelioma, Malignant 281Esophageal Neoplasms 266Mesothelioma 244Colonic Neoplasms 226Brain Neoplasms 217Urinary Bladder Neoplasms 212Triple Negative Breast Neoplasms 212Uterine Cervical Neoplasms 209Endometrial Neoplasms 175Sarcoma 172Carcinoma, Hepatocellular 159NSCLC 136Carcinoma 128Kidney Neoplasms 127

Interventions

palbociclib 1amivantamab 1Tablets 1CB-839 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Solid Tumors × Thoracic × Clear all
NCT06816992 2026-04-24

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

ORIC Pharmaceuticals

Phase 1 Recruiting
76 enrolled
Other solid neoplasmThoracic

Solid Tumors

NCT03965845 2022-09-19

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

Calithera Biosciences, Inc

Phase 1/2 Completed
53 enrolled
Other solid neoplasmThoracic

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡